Enovis (ENOV)
(Delayed Data from NYSE)
$40.22 USD
+1.50 (3.87%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $40.23 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$40.22 USD
+1.50 (3.87%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $40.23 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum C VGM
Zacks News
Enovis (ENOV) Introduces STAR Ankle With e+ Polyethylene
by Zacks Equity Research
Enovis (ENOV) brings the first mobile-bearing ankle system with e+ Polyethylene, which offers enhanced durability, stability and longevity for improved patient outcomes.
Enovis (ENOV) Q2 Earnings Top Estimates
by Zacks Equity Research
Enovis (ENOV) delivered earnings and revenue surprises of 3.33% and 0.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Standard BioTools (LAB) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Standard BioTools (LAB) delivered earnings and revenue surprises of -33.33% and 22.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Enovis (ENOV) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Buy Hims & Hers (HIMS) Stock Ahead of Q2 Earnings?
by Debanjana Dey
Continued solid uptake of Hims & Hers (HIMS) offerings and expanding subscriber base are likely to have driven its performance in the second quarter.
Select Medical's (SEM) Unit Begins IPO Roadshow for 22.5M Shares
by Zacks Equity Research
Select Medical's (SEM) subsidiary, Concentra, starts roadshow for IPO of 22.5 million shares, aiming to list on the NYSE under ticker "CON" with an expected price range of $23-$26 per share.
Zacks.com featured highlights include Energizer, Super League Enterprise and Enovis
by Zacks Equity Research
Energizer, Super League Enterprise and Enovis have been highlighted in this Screen of The Week article.
Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis
by Zacks Equity Research
Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.
Bet on 3 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Energizer (ENR), Super League Enterprise Inc. (SLE) and Enovis (ENOV).
What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release?
by Zacks Equity Research
Quest Diagnostics (DGX) is likely to have maintained its robust base business performance in the second quarter of 2024. However, nosediving COVID-19 testing revenues may limit growth.
Here's How Abbott (ABT) is Placed Ahead of Q2 Earnings Release
by Zacks Equity Research
Abbott Laboratories' (ABT) second-quarter 2024 results are likely to reflect broad-based strength across several businesses and solid progress in the pipeline.
5 Medical Info Systems Stock to Buy for a Stable Portfolio
by Nalak Das
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
Compelling Reasons to Hold on to HCA Healthcare (HCA) Stock
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on the back of improved revenues, a well-diversified healthcare portfolio and solid cash-generating abilities.
Ensign Group (ENSG) Buys Facilities in Arizona & Colorado
by Zacks Equity Research
Ensign Group (ENSG) expands its footprint by acquiring skilled nursing facilities in Arizona and Colorado, enhancing its healthcare services and real estate portfolio.
Zacks Industry Outlook Highlights Hims & Hers Health, Enovis Corp and Health Catalyst
by Zacks Equity Research
Hims & Hers Health, Enovis Corp and Health Catalyst are part of the Zacks Industry Outlook article.
3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.
5 Medical Info Systems Stocks to Buy for Stable Returns
by Nalak Das
We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.
Here's Why Enovis (ENOV) is Poised for a Turnaround After Losing -17.45% in 4 Weeks
by Zacks Equity Research
Enovis (ENOV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -15.45% in 4 Weeks, Here's Why You Should You Buy the Dip in Enovis (ENOV)
by Zacks Equity Research
Enovis (ENOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Enovis (ENOV) Q1 Earnings Match Estimates
by Zacks Equity Research
Enovis (ENOV) delivered earnings and revenue surprises of 0% and 2.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Biotricity Inc. (BTCY) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Biotricity Inc. (BTCY) delivered earnings and revenue surprises of 17.07% and 0.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
GE HealthCare Technologies (GEHC) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
GE HealthCare (GEHC) delivered earnings and revenue surprises of 10.28% and 2.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Acadia (ACHC) is a Smart Addition to Your Portfolio Now
by Zacks Equity Research
Acadia Healthcare's (ACHC) top line is poised to gain from rising admissions and patient days.
Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout
by Zacks Equity Research
Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.
Why Community Health (CYH) Shares Are Attracting Investors Now
by Zacks Equity Research
We expect Community Health's (CYH) occupancy rate to continue moving upward, reflecting improving utilization of its facilities and services.